WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 15-July-2017 (data as of 11-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 48'9401 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 48'4591 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 16'987  16'938  16'889  16'840  16'789  15'926  14'965  14'148 
Births 179  179  178  178  179  197  192  173 
Surviving infants 179  178  178  177  178  196  191  171 
Pop. less than 5 years 894  891  891  890  892  971  934  884 
Pop. less than 15 years 2'818  2'838  2'858  2'873  2'885  2'941  2'724  3'159 
Female 15-49 years 3'729  3'754  3'776  3'798  3'820  3'955  3'975  3'579 

Number of reported cases

(Click for retrospective incidence data for Netherlands (the))
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  140  2'632  10  1'019  16  178 
Mumps
ChartChart
  71  88  39  204  398 
Pertussis
ChartChart
  3'542  6'566  8'960  2'858  13'552  4'836  471  30 
Polio*
ChartChart
 
Rubella
ChartChart
  58  12 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Netherlands (the))
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          95  95  96  97  97  97  97  96 
DTP4          93  94  95 
IPV1         
HepB_BD          99  99  99  99 
HepB3          93  94  92  51  20 
Hib3          95  96  96  97  97  96 
JapEnc         
MCV1          94  95  96  96  96  96  94  91 
MCV2          91  92  93  92  93  96  93 
MenA         
PCV1         
PCV2         
PCV3          94  94  95  96  96 
Pol3          95  95  96  97  97  97  97  96 
Rota1         
RotaC         
RCV1          94  95  96  96  96 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Netherlands (the))
DTP1
  98  98  98  99  99  99  98  98 
DTP3
  95  95  96  97  97  97  97  96 
HepB3
  93  94  92  51  20 
HepB_BD
 
Hib3
  95  96  96  97  97  96 
MCV1
  94  95  96  96  96  96  94  91 
MCV2
  91  92  93  92  93 
PCV3
  94  94  95  96  96 
Pol3
  95  95  96  97  97  97  97  96 
RCV1
  94  95  96  96  96  96  94  91 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 388  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 89
From 80 to 89% 8
From 50 to 79% 3
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 3, 4, 11 months; Yes
DTaPIPV 4 years; Yes
HepB_Adult Yes immigrants from endemic countries
HepB_Pediatric < 48 hours; Yes children of carrier mothers
HPV 12 years, + 6month; Yes
Influenza_Adult >= 60 years; Yes and adults with chronic diseases
Influenza_Pediatric children with chronic diseases
MenC_conj 14 months; Yes
MMR 14 months; 9 years; Yes
Pneumo_conj 2, 4, 11 months; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number

System performance

Total Nº districts in country number 388    393  403  408  415  12 
Nº districts with DTP3 coverage >=80% number 377  379  385  394  400  406   
% of districts with DTP3 coverage >=80% From 0 to 100% 97    98  98  98  98   
Nº districts with measles (MCV1) coverage >=95% number 194  249  283  317  331  329   
% of districts with MCV1 coverage >=95% From 0 to 100% 50    72  79  81  79   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  No  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.